Asia's Innovation Horizon: Insiders Are Optimistic And Wary
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - Multinationals are dropping substantial resources in R&D in Asia, but - excluding Japan - Asian countries have yet to create a significant new drug approval, and opinions differ on when strong INDs will begin to appear out of the region
You may also be interested in...
China's Escalating Scientific Output Tempered By Quality Concerns
TOKYO - Much ink has been devoted to cover the explosion of scientific research being developed in China, but some in the pharma industry charged with identifying potential research partners are troubled with the quality of some research coming out of China
LG Life Science Tops R&D Investment List of Korea-Listed Pharmas
SEOUL - Of the 37 local Korean pharmas listed on Korea's main KOSPI stock market, LG Life Science topped local pharmas in R&D investment last year in both scale and in proportion to its sales, according to a report released by a lawmaker in an Oct. 6 National Assembly session
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).